VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

ipilimumab, vemurafenib
Vaccine Information
  • Vaccine Name: ipilimumab, vemurafenib
  • Target Pathogen: Cancer
  • Target Disease: Cancer
  • Vaccine Ontology ID: VO_0007627
  • Type: monoclonal antibody
  • Status: Research
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Human Response

  • Vaccine Immune Response Type: VO_0003057
  • Immune Response: Ipilimunab is a CTLA-4 receptor is an intracellular receptor upregulated to the T-cell surface upon T-cell activation. Ipilimunab promptly binds with the CTLA-4 receptor, preventing deactivation of the T-cell response; Vemurafenib is a BRAF V600E kinase inhibitor that halts signal trasnduction, resulting in no phosphorylation of the MAPK pathway and ultimately no survival or proliferation of the cell (Culos and Cuellar, 2013).
References
Culos and Cuellar, 2013: Culos KA, Cuellar S. Novel targets in the treatment of advanced melanoma: new first-line treatment options. The Annals of pharmacotherapy. 2013; 47(4); 519-526. [PubMed: 23548648].